Advertisement

The Chinese-German Journal of Clinical Oncology

, Volume 2, Issue 4, pp 213–215 | Cite as

Clinical benefit with intraoperative radiotherapy combined with regional chemotherapy for advanced pancreatic carcinoma

  • Kang Huafeng
  • Wang Xijing
  • Dai Zhijun
  • Liu Xiaoxu
  • Xue Xinghuan
  • Xue Fengjie
  • Ji Zongzheng
Original Articles
  • 13 Downloads

Abstract

Objective: To evaluate the effectiveness of intraoperative radiotherapy (IORT) in combination with regional chemotherapy in the treatment of advanced pancreatic carcinoma.Methods: 17 patients with advanced pancreatic adenocarcinoma were treated with IORT and regional chemotherapy with 5-FU, Epirubucin and Mitomycin, and 6 cases accepted external radiotherapy postoperatively.Results: 35.29% (6/17) of the patients were clinical benefit responders and 23.53% (4/17) had a partial response. The median survival time was 11 months and the 1-year survival rate was 35.29% (6/17)Conclusion: IORT in combination with regional chemotherapy had a good impact on clinical benefit without severe side effects in locally advanced pancreatic carcinoma and led to a significant prolongation of the survival time.

Key words

pancreatic cancer intraoperative radiotherapy chemotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kozuch P, Petryk M, Evans A,et al. Therapy for regionally unresectable pancreatic cancer. Surg Clin North Am, 2001, 81: 691–697.CrossRefPubMedGoogle Scholar
  2. 2.
    Burris HA, Moore MJ, Andersen J,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 1997, 15: 2403–2413.PubMedGoogle Scholar
  3. 3.
    Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer, 1997, 33: S18–22.CrossRefGoogle Scholar
  4. 4.
    Burris H. Objective outcome measures of quality of life. Oncology (Huntingt), 1996, 10: 131–135.Google Scholar
  5. 5.
    Rothenberg ML, Moore MJ, Cripps MC,et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol, 1996, 7: 347–353.CrossRefPubMedGoogle Scholar
  6. 6.
    Fisher BJ, Perera FE, Kocha W,et al. Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys, 1999, 45: 291–295.CrossRefPubMedGoogle Scholar
  7. 7.
    Li JG, Jin HK, Touboul E. Simultaneous chemoradiotherapy for locally advanced pancreatic cancer. Chin J Radiat Oncol, 2001, 10: 232–235.Google Scholar
  8. 8.
    Azria D, Ychou M, Jacto W,et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cis-platin. Pancreas, 2002, 25: 360–365.CrossRefPubMedGoogle Scholar
  9. 9.
    Peng LH, Xu J, Liu TF,et al. The clinical effect of intraoperative radiotherapy and gemcitabine for locally advanced pancreatic cancer. Chin J Cancer Prev Treat, 2002, 9: 323–324.Google Scholar
  10. 10.
    Unal AE, Bayar S, Serinsoz E,et al. Regional chemotherapyinduced cure for pancreatic head carcinoma. Hepatogastroenterology, 2002, 49: 556–557.PubMedGoogle Scholar
  11. 11.
    Ikeda M, Okada S, Tokuuye K,et al. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer, 2001, 91: 490–495.CrossRefPubMedGoogle Scholar
  12. 12.
    Tsuruta K, Okamoto A, Egawa N,et al. Survival benefits of adjuvant chemotherapy with oral doxifluridine (5′-DFUR) following radiotherapy in patients with unresectable pancreatic cancer. J Surg Oncol, 2001, 78: 202–207.CrossRefPubMedGoogle Scholar
  13. 13.
    Snady H, Bruckner H, Cooperman A,et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer, 2000, 89: 314–327.CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2003

Authors and Affiliations

  • Kang Huafeng
    • 1
  • Wang Xijing
    • 1
  • Dai Zhijun
    • 1
  • Liu Xiaoxu
    • 1
  • Xue Xinghuan
    • 1
  • Xue Fengjie
    • 1
  • Ji Zongzheng
    • 1
  1. 1.Department of Oncological Surgery, Second HospitalXi’an Jiaotong UniversityXi’anChina

Personalised recommendations